Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) said its executive team will take part in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 9:30 AM EST.
A webcast will be available via the company’s Investors site after the conference. The summit runs February 11-12, 2026 in New York City.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AKBA declined 2.84%, reflecting a moderate negative market reaction. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $366M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AKBA gained 2.17% while key peers were mixed: AQST -1.11%, ORGO -2.88%, ESPR -0.57%, DVAX +0.13%, SIGA 0%, indicating stock‑specific movement rather than a sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-01-12 | Corporate update | Positive | -7.9% | Outlined Vafseo progress, VOICE/VOCAL timelines, and 2026 pipeline plans. |
| 2026-01-06 | Clinical trial start | Positive | -2.6% | First patient dosed in Phase 2 praliciguat trial for FSGS. |
| 2026-01-05 | Inducement grants | Neutral | -2.6% | Inducement stock options granted to a new employee under Nasdaq rules. |
| 2025-12-01 | Inducement grants | Neutral | -2.6% | Stock options granted to new hires under inducement award program. |
| 2025-12-01 | Pipeline expansion | Positive | -4.4% | Announced establishment of rare kidney disease pipeline with AKB‑097 and praliciguat. |
Recent positive pipeline and corporate updates have been followed by negative share reactions, suggesting a pattern of selling into good news.
Over the last few months, Akebia has focused on expanding its kidney disease pipeline and advancing key programs. On Dec 1, 2025, it established a rare kidney disease pipeline around AKB‑097 and praliciguat. A corporate update on Jan 12, 2026 highlighted Vafseo progress, Phase IV VOICE enrollment (> 2,100 patients), and VOCAL enrollment (~350 patients) with revenue expectations of $5–$6 million for Q4 2025. Despite these developments, shares declined after several of these announcements, contrasting with the neutral nature of today’s conference participation news.
Market Pulse Summary
This announcement centers on Akebia’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, offering additional exposure to institutional investors. It follows recent milestones, including establishment of a rare kidney disease pipeline and advancement of Phase 2 programs. Historical news has often been followed by share price weakness despite constructive updates, and recent SEC filings show equity‑based compensation and planned Rule 144 share sales. Investors may watch future clinical readouts and Vafseo revenue trends for more material catalysts.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12 at 9:30 AM EST.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
The Emerging Outlook: Biotech Summit hosted by Guggenheim Securities, LLC, will take place February 11-12, in New York City.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When will Akebia Therapeutics (AKBA) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?
How can investors watch Akebia Therapeutics (AKBA) Fireside Chat from Guggenheim Biotech Summit 2026?
What is the schedule for the Guggenheim Emerging Outlook: Biotech Summit 2026 where AKBA is speaking?
Who from Akebia Therapeutics will participate in the Guggenheim Biotech Summit 2026 Fireside Chat?
Will the Akebia (AKBA) presentation at Guggenheim 2026 be available on demand after the event?
